Mesenchymal stromal cells, in particular CAR cells, along with having a notable capacity to differentiate into other cell groups, secrete high levels of CXCL12, making them an interesting and potential therapeutic target in the AML scenario (Figure 3). This evidence concerns the gene CXCL12 and acute myeloid leukemia.